secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001628280-23-002417
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Pharma Q1 revenue $62.5M, net loss narrows to $0.39; sells olpasiran royalty for $250M
--------------------------------------------------------------------------------

- Revenue $62.5M vs $27.4M; net loss $41.3M ($0.39/share) improved from $62.9M ($0.60).
- Total cash and investments $617.6M at Dec 31, up from $482.3M at Sep 30.
- Earned $25M milestone from Amgen for olpasiran Phase 3 start, $15M from Horizon for HZN-457 Phase 1 start.
- Sold olpasiran royalty interest to Royalty Pharma for $250M upfront plus up to $160M contingent payments.
- Topline SEQUOIA study: fibrosis regression in 50% of fazirsiran-treated AATD patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/0001628280-23-002417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/arwr-20230206.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer